Apr 08, 2022 By Jazmine Colatriano, M.S. BioSpace Johnson & Johnson’s Janssen Pharmaceutical secured an arbitrary win regarding royalty decisions stemming from the licensing and marketing of daratumumab, an anti-CD38 monoclonal antibody treatment […]
The U.S. Supreme Court on June 21 declined to hear AbbVie Inc.’s challenge to a lower court’s decision that the company violated federal antitrust law by pursuing a “sham” patent complaint against rival Perrigo Co. over AbbVie’s blockbuster testosterone replacement drug AndroGel.
Allele Biotechnology and Pharmaceuticals filed lawsuits against Regeneron Pharmaceuticals, as well as Pfizer and Germany’s BioNTech, claiming the companies infringed on Allele’s patented mNeonGreen technology in the development of their Covid-19 treatments.
Ironwood Pharmaceuticals Inc. and Allergan plc announced that the companies reached an agreement with Mylan Pharmaceuticals Inc. resolving patent litigations brought in response to Mylan’s abbreviated new drug applications seeking approval to market generic versions of Linzess (linaclotide) before the expiration of the companies’ applicable patents.
Bristol-Myers Squibb and Ono Pharmaceutical announced a global patent license agreement with Merck & Co. to settle all patent-infringement litigation related to Merck’s PD-1 antibody Keytruda.
